Unknown

Dataset Information

0

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma.

ABSTRACT:

SUBMITTER: Han L 

PROVIDER: S-EPMC8478646 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
| S-EPMC8202968 | biostudies-literature
Unknown Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
| S-EPMC7877347 | biostudies-literature
Unknown Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma.
| S-EPMC8753190 | biostudies-literature
Unknown High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
| S-EPMC8722124 | biostudies-literature
Unknown Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
| S-EPMC8374046 | biostudies-literature
Unknown A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
| S-EPMC7943908 | biostudies-literature
Unknown Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
| S-EPMC7894235 | biostudies-literature
Unknown Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
| S-EPMC8104258 | biostudies-literature
Unknown Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
| S-EPMC8299593 | biostudies-literature
Unknown Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
| S-EPMC8589080 | biostudies-literature